3 (download XLSX Statistical source data
Garreta E, Gasset D, Semino C, Borros S
(5 mg dosage / 200 mg strength) * 100 mg/mL = injection volume of 2.5mL (5/100) * 100 = 2.5mL Example: Desired dosage is 5mg per injection
Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications
The FDA does not have a special peptide regulatory classification
AOD 9604 may have additional benefits beyond weight loss, including potential improvements in musculoskeletal health, joint pain relief, and more